Company news
CytomX Therapeutics, Inc. news in 2024
CytomX Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
September 8, 2024
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
July 31, 2024
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 17, 2024
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
June 16, 2024
CytomX Therapeutics Announces New Employment Inducement Grants
May 15, 2024
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
May 7, 2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
May 6, 2024
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
April 30, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
April 7, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
April 2, 2024
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
March 20, 2024
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
March 17, 2024
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
March 10, 2024
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
March 3, 2024
CytomX Therapeutics to Present at Upcoming March Investor Conferences
February 26, 2024
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
January 23, 2024
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
January 11, 2024
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
January 3, 2024